Cognyte Software (NASDAQ:CGNT) Sets New 12-Month High at $8.70

Cognyte Software Ltd. (NASDAQ:CGNTGet Free Report) hit a new 52-week high during trading on Tuesday . The stock traded as high as $8.70 and last traded at $7.60, with a volume of 248839 shares traded. The stock had previously closed at $8.01.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. StockNews.com lowered shares of Cognyte Software from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 13th. Needham & Company LLC restated a “hold” rating on shares of Cognyte Software in a research report on Friday, May 17th. Wedbush boosted their target price on shares of Cognyte Software from $5.00 to $8.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Finally, Evercore ISI boosted their target price on shares of Cognyte Software from $5.00 to $7.50 and gave the stock an “in-line” rating in a research report on Wednesday, April 10th.

Get Our Latest Research Report on CGNT

Cognyte Software Trading Down 4.5 %

The firm has a market cap of $543.30 million, a price-to-earnings ratio of -32.65 and a beta of 1.74. The firm has a 50 day moving average price of $7.37 and a 200-day moving average price of $7.08.

Cognyte Software (NASDAQ:CGNTGet Free Report) last issued its earnings results on Tuesday, April 9th. The medical device company reported ($0.28) earnings per share (EPS) for the quarter. Cognyte Software had a negative return on equity of 12.06% and a negative net margin of 4.97%. The firm had revenue of $83.69 million for the quarter. As a group, equities analysts expect that Cognyte Software Ltd. will post -0.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cognyte Software

Institutional investors and hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC purchased a new position in Cognyte Software in the 4th quarter worth approximately $37,000. Covestor Ltd purchased a new position in Cognyte Software in the 1st quarter worth approximately $73,000. Russell Investments Group Ltd. boosted its stake in shares of Cognyte Software by 8,624.3% during the 4th quarter. Russell Investments Group Ltd. now owns 20,066 shares of the medical device company’s stock valued at $129,000 after buying an additional 19,836 shares during the last quarter. Mackenzie Financial Corp boosted its stake in shares of Cognyte Software by 56.1% during the 4th quarter. Mackenzie Financial Corp now owns 21,986 shares of the medical device company’s stock valued at $141,000 after buying an additional 7,899 shares during the last quarter. Finally, Quadrature Capital Ltd purchased a new position in shares of Cognyte Software during the 4th quarter valued at approximately $144,000. Hedge funds and other institutional investors own 72.92% of the company’s stock.

Cognyte Software Company Profile

(Get Free Report)

Cognyte Software Ltd. provides an investigative analytics software to governments and enterprises worldwide. Its Actionable Intelligence for a Safer World, an open software designed to help governments and enterprises accelerate and enhance the effectiveness of investigations. The company offers network intelligence analytics, threat intelligence analytics, decision intelligence analytics, and operational intelligence analytics solutions.

Recommended Stories

Receive News & Ratings for Cognyte Software Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognyte Software and related companies with MarketBeat.com's FREE daily email newsletter.